Hims & Hers Health, Inc. (HIMS)
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers Stock Slips Post Y/Y Q3 Earnings Decline, Margins Contract
HIMS reports lower third-quarter 2025 earnings even as revenue and subscriber growth remain strong across its channels.
Why Hims & Hers Stock May Be a Buy After Mixed Q3 Results
Hims & Hers Health Inc. NYSE: HIMS stock is holding onto a slight gain the day after the company delivered a mixed third-quarter earnings report. The caution centers around the company's valuation, which makes it an outlier among healthcare stocks.
Hims & Hers Health, Inc. (HIMS) Q3 Earnings Match Estimates
Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.09 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.06 per share a year ago.
Hims & Hers Health, Inc. (HIMS) Q3 2025 Earnings Call Transcript
Hims & Hers Health, Inc. ( HIMS ) Q3 2025 Earnings Call November 3, 2025 5:00 PM EST Company Participants Bill Newby Andrew Dudum - Co-Founder, Chairman & CEO Yemi Okupe - Chief Financial Officer Conference Call Participants Justin Patterson - KeyBanc Capital Markets Inc., Research Division Maria Ripps - Canaccord Genuity Corp., Research Division Craig Hettenbach - Morgan Stanley, Research Division Brian Tanquilut - Jefferies LLC, Research Division Eric Percher - Nephron Research LLC Ryan MacDonald - Needham & Company, LLC, Research Division Jungwon Kim - TD Cowen, Research Division Presentation Operator Thank you for standing by. My name is Eric, and I will be your conference operator today.
Hims & Hers Scales AI-Driven Personalized Health and Wellness
HIMS scales AI-driven care with new hormonal health lines, global expansion plans and a $870 million funding boost.
Struggling Healthcare Stock Ripe For Bull Notes
Shares of Hims & Hers Health (HIMS) are headed for their fourth-straight daily drop, down 2.4% to trade at $45.53 at last check, as investors look ahead to the company's third quarter results, due out after the close Monday, Nov. 3. Since hitting a February record high of $72.98, the stock has staged several rallies that have run out of steam around $65.
Can Sustained Product Demand Drive HIMS Stock Before Q3 Earnings?
Hims & Hers benefits from strong platform engagement and hormonal health launches ahead of third-quarter 2025 earnings.
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
Hims & Hers Health, Inc. (HIMS) reached $47.12 at the closing of the latest trading day, reflecting a -2.3% change compared to its last close.
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hims & Hers: Use This Drop Before It's Too Late
Hims & Hers has experienced a hefty sell-off in recent weeks. This sell-off was mainly caused by short-term turbulence, and I expect the company to resolve these issues in the next quarter. HIMS needs to grow in the mid-teens percentage range for the next few years to justify their current valuation.
Hims & Hers Short Interest Nears All-Time High, Buy The Dip?
Shares of Hims & Hers Health Inc. NYSE: HIMS have been the hottest thing in the medical sector, and for good reason. The company's fundamentals are highly attractive for investors who prefer to acquire growth stories early, before they become too large to price in further expansion.
